Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis

Table 1 Descriptions of prognostic risk models for primary biliary cholangitis

	Time of evaluation	Definition of suboptimal treatment response
Rotterdam	1 yr	Abnormal bilirubin and/or albumin
Paris I	1 yr	ALP ≥ 3 × ULN or AST ≥ 2 × ULN or bilirubin > 1 mg/dL
Paris II	1 yr	ALP > 1.5 × ULN or AST > 1.5 × ULN or bilirubin > 1 mg/dL
Barcelona	1 yr	ALP > 1 × ULN and decrease in ALP < 40%
Toronto	2 yr	ALP > 1.67 × ULN
APRI	Baseline	AST/ULN of AST/platelet (× 109) × 100
APRI-r1	1 yr	AST/ULN of AST/platelet (× 109) × 100

ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; APRI: AST to platelet ratio index; APRI-r1: APRI at 1-year; AST: Aspartate aminotransferase; PBC: Primary biliary cholangitis; ULN: Upper limit of normal.